<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Busulphan see Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Malignant effusions; Mitobronitol" /><meta name="IX" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Malignant effusions; Mitobronitol" /><meta name="IXN" content="Busulphan see Busulfan" /><title>8.1.1 Alkylating drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5236-alkylating-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5236-alkylating-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5236-alkylating-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5234-mesna.htm" title="Previous: MESNA">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5253-bendamustine-hydrochloride.htm" title="Next: BENDAMUSTINE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>8.1.1 </span>Alkylating drugs</h1><?highlighter on?><div id="pC" class="jN"><p>Extensive experience is available with these drugs, which are among the most widely used in cancer chemotherapy. They act by damaging DNA, thus interfering with cell replication. In addition to the side-effects common to many cytotoxic drugs (<a title="topic: Side-effects of cytotoxic drugs" href="PHP5183-side-effects-of-cytotoxic-drugs.htm">section 8.1</a>), there are two problems associated with prolonged usage. Firstly, gametogenesis is often severely affected (<a title="target-block: Cytotoxic drugs: Reproductive function" href="PHP5183-side-effects-of-cytotoxic-drugs.htm#PHP5194">section 8.1</a>). Secondly, prolonged use of these drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p> <p id="PHP5238"><strong>Cyclophosphamide</strong> is used mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours. It is given by mouth or intravenously; it is inactive until metabolised by the liver. A urinary metabolite of cyclophosphamide, acrolein, can cause haemorrhagic cystitis; this is a rare but serious complication; increased fluid intake for 24–48 hours after intravenous injection, can prevent this complication. When high-dose therapy (e.g. more than 2 g intravenously) is used or when the patient is considered to be at high risk of cystitis (e.g. because of pelvic irradiation), mesna (given initially intravenously then by mouth) can also help prevent cystitis—see under Urothelial Toxicity (<a title="BNF:monograph-family: Urothelial toxicity" href="PHP5233-urothelial-toxicity.htm">section 8.1</a>).</p> <p id="PHP5240"><strong>Ifosfamide</strong> is related to cyclophosphamide and is given intravenously; mesna (<a title="BNF:monograph-family: Urothelial toxicity" href="PHP5233-urothelial-toxicity.htm">section 8.1</a>) is routinely given with it to reduce urothelial toxicity.</p> <p id="PHP5241"><strong>Chlorambucil</strong> is used either alone or in combination therapy for some lymphomas and chronic leukaemias. It is given by mouth. Side-effects, apart from bone-marrow suppression, are uncommon. However, patients occasionally develop severe widespread rashes which can progress to Stevens-Johnson syndrome or to toxic epidermal necrolysis. If a rash occurs further chlorambucil is contra-indicated and cyclophosphamide is substituted. </p> <p id="PHP5243"><strong>Melphalan</strong> is licensed for the treatment of multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities. Interstitial pneumonitis and life-threatening pulmonary fibrosis are rarely associated with melphalan.</p> <p id="PHP5244"><strong>Busulfan </strong>is given by mouth to treat chronic myeloid leukaemia. Busulfan given by mouth or intravenously, followed by cyclophosphamide, is also licensed as conditioning treatment before haematopoietic stem-cell transplantation in adults and children. Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia. Rarely, progressive pulmonary fibrosis is associated with busulfan. Skin hyperpigmentation is a common side-effect of oral therapy.</p> <p id="PHP5246"><strong>Lomustine</strong> is a lipid-soluble nitrosourea and is given by mouth. It is used mainly to treat Hodgkin's disease resistant to conventional therapy, malignant melanoma and certain solid tumours. Bone-marrow toxicity is delayed, and the drug is therefore given at intervals of 4 to 6 weeks. Permanent bone-marrow damage can occur with prolonged use. Nausea and vomiting are common and moderately severe.</p> <p id="PHP5248"><strong>Bendamustine</strong> given intravenously is licensed for the treatment of chronic lymphocytic leukaemia, non-Hodgkin's lymphoma, and for the treatment of multiple myeloma. </p> <p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (March 2011) that bendamustine (<em>Levact</em>®) is accepted for restricted use within NHS Scotland for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.</p> <div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011)</h3><p>Bendamustine is recommended as an option for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.</p></div> <p id="PHP5249"><strong>Carmustine</strong> given intravenously has similar activity to lomustine; it is given to patients with multiple myeloma, non-Hodgkin's lymphomas, and brain tumours. Cumulative renal damage and delayed pulmonary fibrosis may occur with intravenous use. Carmustine implants are licensed for intralesional use in adults for the treatment of recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also licensed for high-grade malignant glioma as adjunctive treatment to surgery and radiotherapy.</p> <div class="cI"><h3 class="cT">NICE guidance (carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma)</h3><p>See   <a title="target-block: Carmustine implants and temozolomide - high grade glioma" href="PHP5459-dacarbazine-and-temozolomide.htm#PHP5460">Dacarbazine and Temozolomide</a></p></div> <p><strong>Estramustine</strong> is a combination of an oestrogen and chlormethine used predominantly in prostate cancer. It is given by mouth and has both an antimitotic effect and (by reducing testosterone concentration) a hormonal effect.</p> <p id="PHP5251"><strong>Treosulfan</strong> is given by mouth or by intravenous or intraperitoneal administration and is used to treat ovarian cancer. Skin pigmentation is a common side-effect and allergic alveolitis, pulmonary fibrosis and haemorrhagic cystitis occur rarely.</p> <p id="PHP5252"><strong>Thiotepa</strong> is usually used as an intracavitary drug for the treatment of malignant effusions or bladder cancer (<a title=" Bladder instillations and urological surgery" href="PHP5124-bladder-instillations-and-urological-surgery.htm">section 7.4.4</a>). It is also occasionally used to treat breast cancer, but requires parenteral administration.</p> <p><strong>Mitobronitol</strong> is occasionally used to treat chronic myeloid leukaemia; it is available on a named-patient basis from <a title="BNF:appendix: Special-order Manufacturers" href="PHP10403-special-order-manufacturers.htm">specialist importing companies</a>.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5253-bendamustine-hydrochloride"><a href="PHP5253-bendamustine-hydrochloride.htm" title="BENDAMUSTINE HYDROCHLORIDE">BENDAMUSTINE HYDROCHLORIDE</a></li><li id="_PHP5255-busulfan"><a href="PHP5255-busulfan.htm" title="BUSULFAN">BUSULFAN</a></li><li id="_PHP5259-carmustine"><a href="PHP5259-carmustine.htm" title="CARMUSTINE">CARMUSTINE</a></li><li id="_PHP5261-chlorambucil"><a href="PHP5261-chlorambucil.htm" title="CHLORAMBUCIL">CHLORAMBUCIL</a></li><li id="_PHP5265-cyclophosphamide"><a href="PHP5265-cyclophosphamide.htm" title="CYCLOPHOSPHAMIDE">CYCLOPHOSPHAMIDE</a></li><li id="_PHP5268-estramustine-phosphate"><a href="PHP5268-estramustine-phosphate.htm" title="ESTRAMUSTINE PHOSPHATE">ESTRAMUSTINE PHOSPHATE</a></li><li id="_PHP5270-ifosfamide"><a href="PHP5270-ifosfamide.htm" title="IFOSFAMIDE">IFOSFAMIDE</a></li><li id="_PHP5272-lomustine"><a href="PHP5272-lomustine.htm" title="LOMUSTINE">LOMUSTINE</a></li><li id="_PHP5274-melphalan"><a href="PHP5274-melphalan.htm" title="MELPHALAN">MELPHALAN</a></li><li id="_PHP5276-thiotepa"><a href="PHP5276-thiotepa.htm" title="THIOTEPA">THIOTEPA</a></li><li id="_PHP5279-treosulfan"><a href="PHP5279-treosulfan.htm" title="TREOSULFAN">TREOSULFAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5234-mesna.htm">Previous: MESNA</a> | <a class="top" href="PHP5236-alkylating-drugs.htm#">Top</a> | <a accesskey="]" href="PHP5253-bendamustine-hydrochloride.htm">Next: BENDAMUSTINE HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>